TY - JOUR
T1 - Aligned nanofibrillar collagen scaffolds – Guiding lymphangiogenesis for treatment of acquired lymphedema
AU - Hadamitzky, Catarina
AU - Zaitseva, Tatiana S.
AU - Bazalova-Carter, Magdalena
AU - Paukshto, Michael V.
AU - Hou, Luqia
AU - Strassberg, Zachary
AU - Ferguson, James
AU - Matsuura, Yuka
AU - Dash, Rajesh
AU - Yang, Phillip C.
AU - Kretchetov, Shura
AU - Vogt, Peter M.
AU - Rockson, Stanley G.
AU - Cooke, John P.
AU - Huang, Ngan F.
N1 - Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Secondary lymphedema is a common disorder associated with acquired functional impairment of the lymphatic system. The goal of this study was to evaluate the therapeutic efficacy of aligned nanofibrillar collagen scaffolds (BioBridge) positioned across the area of lymphatic obstruction in guiding lymphatic regeneration. In a porcine model of acquired lymphedema, animals were treated with BioBridge scaffolds, alone or in conjunction with autologous lymph node transfer as a source of endogenous lymphatic growth factor. They were compared with a surgical control group and a second control group in which the implanted BioBridge was supplemented with exogenous vascular endothelial growth factor-C (VEGF-C). Three months after implantation, immunofluorescence staining of lymphatic vessels demonstrated a significant increase in lymphatic collectors within close proximity to the scaffolds. To quantify the functional impact of scaffold implantation, bioimpedance was used as an early indicator of extracellular fluid accumulation. In comparison to the levels prior to implantation, the bioimpedance ratio was significantly improved only in the experimental BioBridge recipients with or without lymph node transfer, suggesting restoration of functional lymphatic drainage. These results further correlated with quantifiable lymphatic collectors, as visualized by contrast-enhanced computed tomography. They demonstrate the therapeutic potential of BioBridge scaffolds in secondary lymphedema.
AB - Secondary lymphedema is a common disorder associated with acquired functional impairment of the lymphatic system. The goal of this study was to evaluate the therapeutic efficacy of aligned nanofibrillar collagen scaffolds (BioBridge) positioned across the area of lymphatic obstruction in guiding lymphatic regeneration. In a porcine model of acquired lymphedema, animals were treated with BioBridge scaffolds, alone or in conjunction with autologous lymph node transfer as a source of endogenous lymphatic growth factor. They were compared with a surgical control group and a second control group in which the implanted BioBridge was supplemented with exogenous vascular endothelial growth factor-C (VEGF-C). Three months after implantation, immunofluorescence staining of lymphatic vessels demonstrated a significant increase in lymphatic collectors within close proximity to the scaffolds. To quantify the functional impact of scaffold implantation, bioimpedance was used as an early indicator of extracellular fluid accumulation. In comparison to the levels prior to implantation, the bioimpedance ratio was significantly improved only in the experimental BioBridge recipients with or without lymph node transfer, suggesting restoration of functional lymphatic drainage. These results further correlated with quantifiable lymphatic collectors, as visualized by contrast-enhanced computed tomography. They demonstrate the therapeutic potential of BioBridge scaffolds in secondary lymphedema.
KW - Lymph node transplantation
KW - Lymphangiogenesis
KW - Lymphatic CT-imaging
KW - Lymphatic vessel regeneration
KW - Lymphedema
KW - Nanofibrillar collagen scaffold
KW - Porcine lymphedema model
KW - VEGF-C
UR - http://www.scopus.com/inward/record.url?scp=84975801928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975801928&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2016.05.040
DO - 10.1016/j.biomaterials.2016.05.040
M3 - Article
C2 - 27348849
AN - SCOPUS:84975801928
SN - 0142-9612
VL - 102
SP - 259
EP - 267
JO - Biomaterials
JF - Biomaterials
ER -